iShares Biotechnology ETF (IBB)

NASDAQ: IBB · IEX Real-Time Price · USD
+1.52 (1.22%)
At close: Mar 24, 2023, 4:00 PM
+0.13 (0.10%)
After-hours: Mar 24, 2023, 7:57 PM EDT
Assets $8.35B
Expense Ratio 0.44%
PE Ratio 12.93
Shares Out 66.35M
Dividend (ttm) $0.35
Dividend Yield 0.28%
Ex-Dividend Date Mar 23, 2023
Payout Ratio 4.26%
1-Year Return -3.36%
Volume 1,228,014
Open 124.41
Previous Close 124.35
Day's Range 123.42 - 126.16
52-Week Low 104.29
52-Week High 138.74
Beta 0.85
Holdings 276
Inception Date Feb 5, 2001

About IBB

The iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the ICE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is managed by BlackRock.

Asset Class Equity
Category Health
Region Global
Stock Exchange NASDAQ
Ticker Symbol IBB
Issuer BlackRock
Index Tracked ICE Biotechnology

Top 10 Holdings

53.67% of assets
Name Symbol Weight
Amgen Inc. AMGN 8.18%
Gilead Sciences, Inc. GILD 7.97%
Regeneron Pharmaceuticals, Inc. REGN 7.65%
Vertex Pharmaceuticals Incorporated VRTX 7.58%
Moderna, Inc. MRNA 4.92%
Biogen Inc. BIIB 3.74%
Seagen Inc. SGEN 3.62%
IQVIA Holdings Inc. IQV 3.48%
Illumina, Inc. ILMN 3.40%
Mettler-Toledo International Inc. MTD 3.14%
View More Holdings


Ex-Dividend Amount Pay Date
Mar 23, 2023 $0.060 Mar 29, 2023
Dec 13, 2022 $0.1014 Dec 19, 2022
Sep 26, 2022 $0.15859 Sep 30, 2022
Jun 9, 2022 $0.03053 Jun 15, 2022
Mar 24, 2022 $0.11756 Mar 30, 2022
Dec 13, 2021 $0.04129 Dec 17, 2021
Full Dividend History


ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

1 day ago - Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

3 days ago - Zacks Investment Research

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

1 week ago - InvestorPlace

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

1 week ago - Zacks Investment Research

Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio

Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.

Other symbols: KREXBI
1 week ago - Market Watch

SVB fallout: The impacts on the biotech sector

CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.

Other symbols: SIVBXBI
1 week ago - CNBC Television

The Recent Bullish Trend in IBB, XBI Looks Shaky

Rising interest rates taking steam from rally that powered in IBB and XBI. 

Other symbols: XBI
1 month ago - ETFcom

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

The latest earnings from some of the big biotech players came in at mixed this reporting season.

1 month ago - Zacks Investment Research

5 Least-Hurt Biotech ETFs of the Last Week

Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.

Other symbols: BBHBBPFBTPBE
1 month ago - Zacks Investment Research

Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data

Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors m...

Other symbols: XBI
1 month ago - Reuters

Pharmaceutical companies losing patent protection as competition grows

The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans.

Other symbols: ABBVMRKNVSPFE
1 month ago - CNBC Television

There's a crop of great biotech companies ready to be acquired, says MPM's Christiana Bardon

Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins 'The Exchange' to discuss tailwinds in the pharmaceutical and biotech sector, innovation in obesity drugs, and acquisition ...

Other symbols: XBI
1 month ago - CNBC Television

Why Biotech Is Poised for a Recovery This Year

Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.

Other symbols: XBI
2 months ago - WSJ

Biotech's Blockbuster Week: 3 Stocks to Watch

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

2 months ago - Zacks Investment Research

Subversive Launches ETF to Focus on Mental Health

The debut highlights the lack of funds focused on the area.

2 months ago - ETFcom

4 Market-Beating Top Sector ETFs of Q4 to Buy Now

These four top-ranked sector ETFs topped the market in the ongoing fourth quarter.

3 months ago - Zacks Investment Research

JPMorgan's bullish call on biopharma

The "Halftime Report" traders debate the biggest analyst calls of the day.

Other symbols: ABBVLLYMRKZTS
3 months ago - CNBC Television

Final Trades: IBB, META, TSM & LVS

The traders make their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Courtney Garcia, Steve Grasso and Jeff Mills.

Other symbols: METATSMLVS
4 months ago - CNBC Television

ETFs Find a Role in a Long-Term Portfolio

Albion Financial's Jason Ware sees funds as mainstays in ‘core-satellite' planning.

Other symbols: IJRXLE
4 months ago - ETFcom

We still think there's more room for biotech to go higher, says Jefferies' Yee

Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late ...

Other symbols: VRTX
4 months ago - CNBC Television

If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong

Dr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Bioscienc...

Other symbols: ACETMATXRNA
4 months ago - CNBC Television

How Are Biotech ETFs Reacting to Q3 Earnings Releases?

Biotech earnings have come in upbeat in the third quarter.

Other symbols: BBHXBI
4 months ago - Zacks Investment Research

XBI vs IBB: what's a better way to play the biotech space?

Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.

Other symbols: XBI
5 months ago - Invezz

Final Trades: Biotech, Treasuries & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: HYGJEPITBF
5 months ago - CNBC Television

Biotech is going to have a hard time until the end of rate cycle, says E Squared's Les Funtleyder

Les Funtleyder, E Squared Capital Management portfolio manager, joins 'Power Lunch' to discuss his favorite stocks for Q4, how long it'll be until the small- and mid-cap biotech stocks move higher and...

6 months ago - CNBC Television